Stiripentol in severe myoclonic epilepsy in infancy: a randomised placebo-controlled syndrome-dedicated trial
The DOI matches its Crossref record; 25 of the 25 references it cites were found in a registry or an index.
Abstract
Background Stiripentol is an inhibitor of cytochrome P450 that showed antiepileptic efficacy in severe myoclonic epilepsy in infancy (SMEI) in association with clobazam and valproate in an open study. To confirm these results, 41 children with SMEI were included in a randomised, placebo-controlled, add-on trial. Methods After a baseline period of 1 month, placebo (n=20) or stiripentol (n=21) was added to valproate and clobazam during a double-blind period of 2 months. Patients then received stiripentol in an open fashion. Responders were defined as having more than 50% reduction in the frequency of clonic (or tonic-clonic) seizures during the second month of the double-blind period compared with baseline. Findings 15 (71%) patients were responders on stiripentol (including nine free of clonic or tonic-clonic seizures), whereas there was only one (5%) on placebo (none were seizure free; stiripentol 95% CI 52.1-90.7 vs placebo 0-14.6). The 95% CI of the difference was 42.2-85.7. Percentage of change from baseline was higher on stiripentol (-69%) than on placebo (+7%), p Interpretation This controlled trial shows the antiepileptic efficacy, of add-on stiripentol in children with SMEI. The results also provide good reason to focus studies on a specific epilepsy syndrome-a small sample of patients is sufficient to show the efficacy that might have been missed in a heterogeneous population.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“In Dravet syndrome, a RCT of stiripentol demonstrated clear efficacy 193 , after initially being trialled in drug-resistant epilepsy.”
From Developmental and epileptic encephalopathies (2024) · cites this paper as [193]
In the citing paper
“In a RCT on stable doses of clobazam and valproate, 71% of children with Dravet syndrome receiving add-on stiripentol compared with only 5% receiving placebo achieved a >50% reduction in seizures 193 .”
From Developmental and epileptic encephalopathies (2024) · cites this paper as [193]
Citations
Cites
Double-blind comparison of lamotrigine and carbamazepine in newly diagnosed epilepsy
Brodie, M. J., UK Lamotrigine/Carbamazepine Monotherapy Trial Group, Richens, A., & Yuen, A. (1995) · The Lancet · doi:10.1016/s0140-6736(95)90581-2 · Cited by 615
Lamotrigine and Seizure Aggravation in Severe Myoclonic Epilepsy
Guerrini, R., Dravet, C., Genton, P., Belmonte, A., Kaminska, A., & Dulac†, O. (1998) · Epilepsia · doi:10.1111/j.1528-1157.1998.tb01413.x · Cited by 467
Self-citationEfficacy of Felbamate in Childhood Epileptic Encephalopathy (Lennox-Gastaut Syndrome)
(1993) · New England Journal of Medicine · doi:10.1056/nejm199301073280105 · Cited by 407
A double-blind, randomized trial of topiramate in Lennox–Gastaut syndrome
Sachdeo, R. C., Glauser, T. A., Ritter, F., Reife, R., Lim, P., Pledger, G., & the Topiramate YL Study Group (1999) · Neurology · doi:10.1212/wnl.52.9.1882 · Cited by 380
Lamotrigine for Generalized Seizures Associated with the Lennox–Gastaut Syndrome
Motte, J., Trevathan, E., Arvidsson, J. F. V., Barrera, M. N., Mullens, E. L., & Manasco, P. (1997) · New England Journal of Medicine · doi:10.1056/nejm199712183372504 · Cited by 359
Dichter, M. A., & Brodie, M. J. (1996) · New England Journal of Medicine · doi:10.1056/nejm199606133342407 · Cited by 340
Chiron, C., Dumas, C., Jambaqué, I., Mumford, J., & Dulac, O. (1997) · Epilepsy Research · doi:10.1016/s0920-1211(96)01006-6 · Cited by 310
Self-citationGuerreiro, M. M., Vigonius, U., Pohlmann, H., de Manreza, M. L. G., Fejerman, N., Antoniuk, S. A., & Moore, A. (1997) · Epilepsy Research · doi:10.1016/s0920-1211(97)00025-9 · Cited by 241
Therapeutic Trial of Vigabatrin in Refractory Infantile Spasms
Chiron, C., Dulac, O., Beaumont, D., Palacios, L., Pajot, N., & Mumford, J. (1991) · Journal of Child Neurology · doi:10.1177/0883073891006002101 · Cited by 235
Self-citation
Research works printed but not linked: 3
- Peters, 1996, Vigabatrin as first-line monotherapy in newly diagnosed infantile spasms: a placebocontrolled double-blind study, Epilepsia, 37, 118
- Elterman, 1997, Topiramate YP study team. A double-blind trial of topiramate in partial seizures in children, Epilepsia, 38, S131
- Levy, 1987, Effect of stiripentol on valproate plasma concentration and metabolism, Epilepsia, 28, 605
Cited by
Patsalos, P. N., Berry, D. J., Bourgeois, B. F. D., Cloyd, J. C., Glauser, T. A., Johannessen, S. I., Leppik, I. E., Tomson, T., & Perucca, E. (2008) · Epilepsia · doi:10.1111/j.1528-1167.2008.01561.x · Cited by 1,156
“Stiripentol is an inhibitor of clobazam and, more potently, of N-desmethylclobazam metabolism and it increases serum N-desmethylclobazam concentrations several-fold (Chiron et al., 2000; Giraud et al., 2006).”
BackgroundGuerrini, R. (2006) · The Lancet · doi:10.1016/s0140-6736(06)68182-8 · Cited by 848
Modern antiepileptic drug development has failed to deliver: Ways out of the current dilemma
Löscher, W., & Schmidt, D. (2011) · Epilepsia · doi:10.1111/j.1528-1167.2011.03024.x · Cited by 590
“Although the introduction of several new AEDs as orphan drugs such as stiripentol for Dravet syndrome (Chiron et al., 2000), rufinamide for refractory Lennox-Gastaut syndrome (Glauser et al., 2008), and brivaracetam for symptomatic myoclonus (U.S.A.) can, in general, be considered as a therapeutic…”
BackgroundTherapeutic Drug Monitoring of Antiepileptic Drugs in Epilepsy: A 2018 Update
Patsalos, P. N., Spencer, E. P., & Berry, D. J. (2018) · Therapeutic Drug Monitoring · doi:10.1097/ftd.0000000000000546 · Cited by 477
“The reference range for stiripentol in plasma of Dravet syndrome patients is 8-12 mg/L.(120) For controlling absence seizures in children the reference range is 4-22 mg/L.”
BackgroundProgress report on new antiepileptic drugs: A summary of the Eigth Eilat Conference (EILAT VIII)
Bialer, M., Johannessen, S. I., Kupferberg, H. J., Levy, R. H., Perucca, E., & Tomson, T. (2007) · Epilepsy Research · doi:10.1016/j.eplepsyres.2006.10.008 · Cited by 477
Metadata
- Authors
- Chiron, C., Marchand, M., Tran, A., Rey, E., d'Athis, P., Vincent, J., Dulac, O., & Pons, G.
- Affiliations
- Inserm (FR)
- Hôpital Saint-Vincent-de-Paul (FR)
- Corresponding author
- Chiron, C
- Venue
- The Lancet
- Publisher
- Elsevier BV
- Published
- 2000-11
- Volume
- 356
- Issue
- 9242
- Pages
- 1638-1642
- ISSN
- 0099-5355 (ISSN-L)
- 0140-6736
- OpenAlex
- W2101383744
- Cited by
- 568
- References
- 25
- Citations by year
- 2026: 15 · 2025: 29 · 2024: 30 · 2023: 27 · 2022: 24 · 2021: 32 · 2020: 30 · 2019: 44 · 2018: 20 · 2017: 23 · 2016: 20 · 2015: 26 · 2014: 27 · 2013: 29 · 2012: 26
- FWCI
- 6.55
- Type
- journal article
- Language
- en
- Open access
- closed
- Licence
- www.elsevier.com/tdm/userlicense/1.0/ (tdm)
- Locations
- The Lancet (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Health Sciences › Medicine › Clinical Neurology › Epilepsy research and treatment
- Health Sciences › Medicine › Pediatrics, Perinatology and Child Health › Pharmacological Effects and Toxicity Studies
- Health Sciences › Medicine › Physiology (medical) › Diet and metabolism studies
- Keywords
- stiripentol, Dravet syndrome, antiepileptic drug efficacy, adjunctive therapy, valproic acid, clobazam, seizure frequency reduction, pediatric epilepsy, adverse drug reactions
- MeSH terms
- Clobazam, Anticonvulsants, Benzodiazepines, Child, Preschool, Dioxolanes, Double-Blind Method, Drug Therapy, Combination, Epilepsies, Myoclonic, Female, Humans, Infant, Male, Syndrome, Anti-Anxiety Agents, Valproic Acid
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Stiripentol in severe myoclonic epilepsy in infancy: a randomised placebo-controlled syndrome-dedicated trial. https://app.cochat.ai/papers/10.1016/s0140-6736(00)03157-3
- The paper
- Chiron, C., Marchand, M., Tran, A., Rey, E., d'Athis, P., Vincent, J., Dulac, O., & Pons, G. (2000). Stiripentol in severe myoclonic epilepsy in infancy: a randomised placebo-controlled syndrome-dedicated trial. The Lancet. https://doi.org/10.1016/s0140-6736(00)03157-3
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.